PubMed:10364497 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/10364497","sourcedb":"PubMed","sourceid":"10364497","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/10364497","text":"High-yield reassortant influenza vaccine production virus has a mutation at an HLA-A 2.1-restricted CD8+ CTL epitope on the NS1 protein.\nCurrent influenza virus vaccines are prepared using high-yield reassortant virus strains obtained from a mixed infection of the new virus strain and a prototype high-yielding virus strain. The high-titered reassortant virus strain used as vaccine seed virus possesses the recent virus HA and NA and contains the internal genes from the high-growing prototype parent. We established a human CD8(+) cytotoxic T cell (CTL) line, 10-2C2, which recognizes an HLA-A2.1-restricted influenza A virus H1, H2, H3 cross-reactive T cell epitope on amino acids 122-130 of the NS1 protein, and unexpectedly we observed that there was decreased lysis of target cells infected with the A/Texas/36/91 (H1N1) vaccine virus strain compared to the lysis of target cells infected with the prototype A/PR/8/34 (H1N1) virus. RT-PCR results showed that the A/Texas vaccine virus strain contained a quasispecies. Approximately 50% of viral RNA of the NS1 gene had a nucleotide substitution that resulted in the N --\u003e K amino acid change at the sixth position of the nonamer peptide. Current influenza vaccines are inactivated and do not contain the NS1 protein; however, future influenza vaccines may include live attenuated vaccines and with this mutation a live virus would fail to induce a CD8(+) CTL response to this epitope in individuals with HLA-A2.1, a very common allele, and potentially have reduced efficacy.","tracks":[{"project":"IAV-Glycan_IAV_human_2","denotations":[{"id":"T1","span":{"begin":64,"end":72},"obj":"mutation"},{"id":"T2","span":{"begin":422,"end":424},"obj":"HA"},{"id":"T3","span":{"begin":429,"end":431},"obj":"NA"},{"id":"T4","span":{"begin":629,"end":631},"obj":"H1"},{"id":"T5","span":{"begin":633,"end":635},"obj":"H2"},{"id":"T6","span":{"begin":637,"end":639},"obj":"H3"},{"id":"T7","span":{"begin":822,"end":826},"obj":"H1N1"},{"id":"T8","span":{"begin":926,"end":930},"obj":"H1N1"},{"id":"T9","span":{"begin":1089,"end":1101},"obj":"substitution"},{"id":"T10","span":{"begin":1360,"end":1368},"obj":"mutation"}],"attributes":[{"subj":"T1","pred":"source","obj":"IAV-Glycan_IAV_human_2"},{"subj":"T2","pred":"source","obj":"IAV-Glycan_IAV_human_2"},{"subj":"T3","pred":"source","obj":"IAV-Glycan_IAV_human_2"},{"subj":"T4","pred":"source","obj":"IAV-Glycan_IAV_human_2"},{"subj":"T5","pred":"source","obj":"IAV-Glycan_IAV_human_2"},{"subj":"T6","pred":"source","obj":"IAV-Glycan_IAV_human_2"},{"subj":"T7","pred":"source","obj":"IAV-Glycan_IAV_human_2"},{"subj":"T8","pred":"source","obj":"IAV-Glycan_IAV_human_2"},{"subj":"T9","pred":"source","obj":"IAV-Glycan_IAV_human_2"},{"subj":"T10","pred":"source","obj":"IAV-Glycan_IAV_human_2"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"IAV-Glycan_IAV_human_2","color":"#b3ec93","default":true}]}]}}